Summary
AbbVie Inc. (ABBV) filed a Form 8-K on January 31, 2014, primarily to report its financial results for the fourth quarter and full year ended December 31, 2013. The filing itself is brief, noting that the company issued a press release on the same date to announce these results. This press release, furnished as Exhibit 99.1, contains the detailed financial information that investors should review for insights into AbbVie's performance.
Key Highlights
- 1AbbVie Inc. reported its Q4 and Full Year 2013 financial results on January 31, 2014.
- 2The 8-K filing serves as a cover for the press release containing the detailed financial results.
- 3The press release, Exhibit 99.1, is the primary source of financial performance information for the period.
- 4The filing confirms the company's ongoing reporting of financial operational results.
- 5William J. Chase, Executive Vice President and Chief Financial Officer, signed the filing.
Frequently Asked Questions
The main purpose of this Form 8-K filing is to officially report AbbVie Inc.'s financial results for the fourth quarter and the full fiscal year 2013, as announced in their press release dated January 31, 2014.
The actual detailed financial results are not included directly in the 8-K filing itself. They are provided in the press release dated January 31, 2014, which is furnished as Exhibit 99.1 to this report and incorporated by reference.
No, this specific 8-K filing (Item 2.02) is solely focused on reporting past financial results and does not contain any new strategic information, business updates, or forward-looking statements beyond what would typically be found in a results announcement press release.